Medicus Pharma Ltd. (MDCXW) shareholders
Close on Oct 30, 2026Market cap $118.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bokhari, Raza | 4,859,349 | 5.30% | 13D (active) | Sep 4, 2026 |
| Ajay Raju Joint filing with 215 Capital Togo PHL Fund I, LP (16.90%), Togo PHL Management LLC (16.90%) | 2,000,000 | 16.90% | 13G (passive) | Dec 31, 2024 |
| SkinJect Partners LLC Joint filing with John Hathaway (6.80%) | 800,952 | 6.80% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDCXW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 60,600 | – | $39.39K | – | 0.00% |
| Anson Funds Management LP | 42,400 | – | $18.92K | −42,400 | 0.00% |
| Connective Capital Management, LLC | 6,000 | – | $3.90K | – | 0.00% |
| UBS Group AG | 2,203 | – | $1.43K | +738 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0 / 1 | 1 / 2 | 0M | 0M |
| Q1 2026 | 6 | 0M | 1 / 1 | 0 / 0 | 0M | 0M |
| Q4 2025 | 5 | 0M | 1 / 1 | 0 / 1 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0 / 1 | 1 / 0 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0 / 1 | 1 / 2 | 0M | 0M |
| Q1 2025 | 7 | 0M | 2 / 3 | 0 / 1 | 0M | 0M |
| Q4 2024 | 6 | 0M | 6 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Raza Bokhari | Chief Executive Officer, Director | 3,734,349 | Sep 8, 2026 |
| Andrew Alasdair Smith | Chief Operating Officer | 735,458 | Sep 8, 2026 |
| Carolyn F. Bonner | President and CFO | 1,489,493 | Sep 8, 2026 |
| Edward J. Brennan | Chief Scientific Officer | 674,735 | Sep 8, 2026 |
| Faisal Mehmud | Chief Medical Officer | 1,470,588 | Sep 8, 2026 |
| James P. Quinlan | Chief Financial Officer | 274,147 | Aug 14, 2025 |
| Patrick J. Mahaffy | Director | 35,435 | Jun 4, 2026 |
| William Ashton | Director | 1,250 | Jun 4, 2026 |
| Barry Fishman | Director | – | Jun 4, 2026 |
| Ajay Raju | Director | – | Jun 4, 2026 |
| Robert J. Ciaruffoli | Director | 12,500 | Jun 4, 2026 |
| Sara R. May | Director | – | Jun 4, 2026 |
| Larry Kaiser | Director | – | Jun 4, 2026 |
| Cathy McMorris Rodgers | Director | – | Jun 4, 2026 |
| Frank W. Lavelle | Director | 25,622 | Jan 23, 2025 |
| Velocity Fund Partners, Lp | 10% owner | 3,323,741 | May 21, 2025 |
| Kenneth R. Melani | 10% owner | 3,658,152 | May 21, 2025 |
| PHL Management LLC Togo | 10% owner | – | Dec 31, 2024 |
| 215 Capital TOGO PHL Fund I, LP | 10% owner | 2,000,000 | Dec 31, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Edward J. Brennan Chief Scientific Officer | Sep 4, 2026 | Award | +588,235 | $0.17 | $100.00K | 674,735 |
| Raza Bokhari Chief Executive Officer, Director | Sep 4, 2026 | Award | +2,941,176 | $0.17 | $500.00K | 2,941,176 |
| Andrew Alasdair Smith Chief Operating Officer | Sep 4, 2026 | Award | +735,294 | $0.17 | $125.00K | 735,458 |
| Faisal Mehmud Chief Medical Officer | Sep 4, 2026 | Award | +1,470,588 | $0.17 | $250.00K | 1,470,588 |
| Carolyn F. Bonner President and CFO | Sep 4, 2026 | Award | +1,470,588 | $0.17 | $250.00K | 1,489,493 |
| James P. Quinlan Chief Financial Officer | Aug 13, 2025 | Option exercise | +20,000 | $2.75 | $55.00K | 274,147 |
| James P. Quinlan Chief Financial Officer | Aug 13, 2025 | Option exercise | +125,000 | $0.81 | $101.25K | 254,147 |
| Kenneth R. Melani 10% owner | May 20, 2025 | Sale | −75,000 | $7.72 | $579.00K | 3,248,741 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Medicus Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 177 shares on Sep 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Velocity Fund Partners, Lp Major Shareholders | May 20, 2025 | 118,000 | $23.07M | May 20, 2025 | Merger |